NASDAQ · Biotechnology

ImmuCell Corporation (ICCC) Stock

$9.80 +0.51% NASDAQ: ICCC Healthcare

Valuation

MetricValue
Price$9.80
Market Cap$88.66M
P/E Ratio115.25
P/B Ratio2.82
P/S Ratio2.88
EPS (TTM)$-0.12
52-Week High$12.10
52-Week Low$4.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2.68%
ROA1.69%
ROCE9.16%
Gross Margin7.14%
Operating Margin7.14%
Net Margin2.57%
Debt/Equity0.40
Current Ratio4.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$19.0M$17.0M$26.0M$28.0M
Operating Profit$0$-2.0M$-6.0M$-2.0M$2.0M
Net Profit$0$-2.0M$-6.0M$-2.0M$-1.0M
EPS$-0.01$-0.32$-0.75$-0.26$-0.12
Op Margin1.3%-12.4%-32.9%-6.2%6.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$44.0M$45.0M$44.0M$45.0M$43.0M
Total Liabilities$12.0M$14.0M$19.0M$18.0M$15.0M
Cash$10.0M$6.0M$1.0M$4.0M$4.0M
Borrowings$10.0M$12.0M$17.0M$15.0M$13.0M

Latest News

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand Zacks · Jul 10, 2026 ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results GlobeNewswire · Jul 9, 2026 The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell Zacks · Jun 26, 2026 Top Stock Reports for JPMorgan, Novartis & Qualcomm Zacks · Jun 25, 2026 ICCC's Valuation Remains Premium: Is it Worth Overpaying for? Zacks · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$1.0M$-2.0M$-5.0M$0$2.0M
Investing Cash Flow$-4.0M$-8.0M$-4.0M$-1.0M$-2.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$3.0M$-4.0M$-5.0M$3.0M$0
Free Cash Flow$-2.0M$-6.0M$-7.0M$0$1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.30
EV / EBITDA25.96
FCF Yield4.78%
Quick Ratio2.71
Interest Coverage8.93
Return 1Y82.11%
Return 3Y123.97%
Return 5Y25.00%

Ownership

Insiders Held32.13%
Institutions Held21.62%
Institutions Float Held31.86%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC260,3272026-03-31
Morgan Stanley221,7162026-03-31
Renaissance Technologies, LLC151,7892026-03-31
Cresset Asset Management, LLC135,2672026-03-31
Bleichroeder LP101,5942026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
CUECue Biopharma, Inc. $27.66 +23.87% -0.95 $200.93M 0.00%
EQEquillium, Inc. $1.41 -2.08% -5.50 $89.15M 0.00%
FBIOFortress Biotech, Inc. $2.13 +2.15% 0.64 $70.92M 0.00%
GNTAGenenta Science S.p.A. $1.50 -5.66% -3.98 $28.72M 0.00%

About ImmuCell Corporation

ImmuCell Corporation is led by CEO F. Olivier Te Boekhorst, employs 69 people, headquartered in US, publicly traded since 1987.

ImmuCell Corporation (ICCC) stock trades at $9.80 with a market capitalization of $88.66M. The stock is valued at a price-to-earnings (P/E) ratio of 115.25, price-to-book of 2.82, price-to-sales of 2.88. Over the past 52 weeks the stock has ranged between $4.52 and $12.10, and currently trades 19.0% below its 52-week high.

On profitability, ImmuCell Corporation generates a return on equity (ROE) of 2.68%, return on capital employed of 9.16%, an operating margin of 7.14%, a net profit margin of 2.57%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.